Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 7:12 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 7:12 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump
by Zacks Equity Research
This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
by Zacks Equity Research
Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Growth in t:slim X2 insulin pump sales is expected to get reflected in Tandem Diabetes' (TNDM) upcoming quarterly results.
Tandem (TNDM) Catches Eye: Stock Jumps 9.5%
by Zacks Equity Research
Tandem (TNDM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.
Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds
by Zacks Equity Research
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
Tandem Diabetes Care Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Will Tandem Diabetes Care Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Tandem Diabetes Care.
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, Skechers, Tandem, CyberArk and Fortinet
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
Beyond Earnings Growth: Focus on Beat With These 5 Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next release.
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
5 Top-Ranked Stocks Primed for an Earnings Beat
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
by Nalak Das
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Releases Positive Results Of t:slim X2 Pump Studies
by Zacks Equity Research
The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.
Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.